Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

A general approach for investigating enzymatic pathways and substrates for ubiquitin-like modifiers.

Li T, Santockyte R, Shen RF, Tekle E, Wang G, Yang DC, Chock PB.

Arch Biochem Biophys. 2006 Sep 1;453(1):70-4. Epub 2006 Mar 20.

PMID:
16620772
2.

Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways.

Schulman BA, Harper JW.

Nat Rev Mol Cell Biol. 2009 May;10(5):319-31. doi: 10.1038/nrm2673. Epub 2009 Apr 8. Review.

3.

SUMO conjugation and cardiovascular development.

Wang J.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1219-29. Review.

PMID:
19273126
4.

Identification of cross talk between SUMOylation and ubiquitylation using a sequential peptide immunopurification approach.

McManus FP, Lamoliatte F, Thibault P.

Nat Protoc. 2017 Nov;12(11):2342-2358. doi: 10.1038/nprot.2017.105. Epub 2017 Oct 19.

PMID:
29048423
5.

Innate link between NF-kappaB activity and ubiquitin-like modifiers.

Lang V, Rodríguez MS.

Biochem Soc Trans. 2008 Oct;36(Pt 5):853-7. doi: 10.1042/BST0360853.

PMID:
18793150
6.

A universal strategy for proteomic studies of SUMO and other ubiquitin-like modifiers.

Rosas-Acosta G, Russell WK, Deyrieux A, Russell DH, Wilson VG.

Mol Cell Proteomics. 2005 Jan;4(1):56-72. Epub 2004 Nov 30.

7.

A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier.

Komatsu M, Chiba T, Tatsumi K, Iemura S, Tanida I, Okazaki N, Ueno T, Kominami E, Natsume T, Tanaka K.

EMBO J. 2004 May 5;23(9):1977-86. Epub 2004 Apr 8.

8.

NEDD8 pathways in cancer, Sine Quibus Non.

Watson IR, Irwin MS, Ohh M.

Cancer Cell. 2011 Feb 15;19(2):168-76. doi: 10.1016/j.ccr.2011.01.002. Review.

9.

A targeted proteomic analysis of the ubiquitin-like modifier nedd8 and associated proteins.

Jones J, Wu K, Yang Y, Guerrero C, Nillegoda N, Pan ZQ, Huang L.

J Proteome Res. 2008 Mar;7(3):1274-87. doi: 10.1021/pr700749v. Epub 2008 Feb 5.

10.

DeSUMOylating enzymes--SENPs.

Drag M, Salvesen GS.

IUBMB Life. 2008 Nov;60(11):734-42. doi: 10.1002/iub.113. Review.

11.

Protein modification by SUMO.

Johnson ES.

Annu Rev Biochem. 2004;73:355-82. Review.

PMID:
15189146
12.

Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins.

Hemelaar J, Borodovsky A, Kessler BM, Reverter D, Cook J, Kolli N, Gan-Erdene T, Wilkinson KD, Gill G, Lima CD, Ploegh HL, Ovaa H.

Mol Cell Biol. 2004 Jan;24(1):84-95.

13.

Structural attributes in the conjugation of ubiquitin, SUMO and RUB to protein substrates.

Goettsch S, Bayer P.

Front Biosci. 2002 Aug 1;7:a148-62. Review.

PMID:
12133807
14.

Role of UbL family modifiers and their binding proteins in cell signaling.

van Wijk SJ, Bienko M, Dikic I.

Methods Mol Biol. 2012;832:163-71. doi: 10.1007/978-1-61779-474-2_11.

PMID:
22350884
15.
16.

Novel substrates and functions for the ubiquitin-like molecule NEDD8.

Xirodimas DP.

Biochem Soc Trans. 2008 Oct;36(Pt 5):802-6. doi: 10.1042/BST0360802. Review.

PMID:
18793140
17.

Protein-protein interactions regulate Ubl conjugation.

Knipscheer P, Sixma TK.

Curr Opin Struct Biol. 2007 Dec;17(6):665-73. Epub 2007 Oct 15.

PMID:
17933515
18.

ISG15: the immunological kin of ubiquitin.

Ritchie KJ, Zhang DE.

Semin Cell Dev Biol. 2004 Apr;15(2):237-46. Review.

PMID:
15209384
19.

Positive and negative regulation of APP amyloidogenesis by sumoylation.

Li Y, Wang H, Wang S, Quon D, Liu YW, Cordell B.

Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):259-64. Epub 2002 Dec 27. Erratum in: Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9102.

20.

Ubiquitin-like protein modifiers and their potential for antiviral and anti-HCV therapy.

Chen L, Li S, Li Y, Duan X, Liu B, McGilvray I.

Expert Rev Proteomics. 2013 Jun;10(3):275-87. doi: 10.1586/epr.13.15. Review.

PMID:
23777217

Supplemental Content

Support Center